To the text
To main menu
To header menu
To footer menu

Home
News

News

Year

Category

2024

Holdings Organization July 1, 2024: Announcement of new structure

Holdings Finance February 13, 2024: Notice of Consolidation of Shares, Abolition of the Provision of Shares Constituting One Share Unit, and Partial Amendment to the Articles of Incorporation

Holdings Finance February 13, 2024: Notice Regarding Cancellation of Treasury Shares

Holdings Finance February 13, 2024: The 3rd Quarter of Fiscal 2023 Financial Statements

Holdings Finance January 16, 2024: Notice Regarding the Results of the Tender Offer by Otemon Co., Ltd. for the Company Shares Etc. and Change of the Parent Company and the Largest Shareholder Among the Major Shareholders

Group Company Products January 16, 2024: Launch of Nanozora® 30mg Autoinjector for S.C. Injection

2023

Group Company Products December 1, 2023: Notification of the Approval of Home Self-injection Guidance and Management Fees and the Derestriction of the Dosing Period for Nanozora^Ⓡ

Holdings Finance November 24, 2023: Announcement of Implementation of MBO and Recommendation for Tender Offer

Holdings Finance November 24, 2023: Announcement of Revision of Dividend Forecast for the Fiscal Year Ending March 31, 2024 (No Dividend)

Holdings Finance November 10, 2023: The 2nd Quarter of Fiscal 2023 Financial Statements

Holdings Finance November 10, 2023: Reference Data of The 2nd Quarter of Fiscal 2023 Financial Statements

Holdings Finance August 7, 2023: Notice Concerning Determination of Details of Stock Options (Stock Acquisition Rights)

Holdings Finance August 4, 2023: The 1st Quarter of Fiscal 2023 Financial Statements

Holdings Finance August 4, 2023: Reference Data of The 1st Quarter of Fiscal 2023 Financial Statements

Group Company R&D August 1, 2023: Notification of Approval to Manufacture and Market Nanozora® 30mg Autoinjectors for S.C. Injection in Japan

Holdings Finance June 29, 2023: Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)

Holdings Finance June 29, 2023: Notice of Resolution at the 12th Ordinary General Meeting of Shareholders

Group Company Corporate June 21, 2023: Taisho Pharmaceutical and Biolinq Announce Strategic Collaboration and Exclusive License Agreement in Japan

Holdings Finance May 11, 2023: Financial Statements for Fiscal 2022

Holdings Finance May 11, 2023: Reference Data of Financial Statements for Fiscal 2022

Holdings Finance February 9, 2023: The 3rd Quarter of Fiscal 2022 Financial Statements

Holdings Finance February 9, 2023: Reference Data of The 3rd Quarter of Fiscal 2022 Financial Statements

Holdings Finance February 9, 2023: Notice of Revision of Forecasts for the Fiscal Year Ending March 31, 2023

2022

Group Company Products December 1, 2022: Launch of Nanozora® 30 mg Syringes for Subcutaneous Injection

Group Company Corporate November 24, 2022: Transfer and Future Marketing of Osteoporosis Agent Bonviva in Japan

Holdings Finance November 10, 2022: The 2nd Quarter of Fiscal 2022 Financial Statements

Holdings Finance November 10, 2022: Reference Data of The 2nd Quarter of Fiscal 2022 Financial Statements

Group Company R&D September 28, 2022: Notification of Application for Approval to Manufacture and Market Rheumatoid Arthritis Therapy Nanozora® 30mg Autoinjectors for S.C. Injection in Japan

Group Company R&D September 26, 2022: Notification of Approval to Manufacture and Market Nanozora® 30mg Syringes for S.C. Injection, a Therapy for Rheumatoid Arthritis, in Japan Japan's First NANOBODY® Therapeutic

Group Company R&D August 5, 2022: Cetylpyridinium chloride hydrate (CPC) confirmed to have an action of inactivating SARS-CoV-2 variants

Holdings Finance August 3, 2022: The 1st Quarter of Fiscal 2022 Financial Statements

Holdings Finance August 3, 2022: Reference Data of The 1st Quarter of Fiscal 2022 Financial Statements

Holdings Finance June 29, 2022: Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)

Holdings Finance May 13, 2022: Financial Statements for Fiscal 2021

Holdings Finance May 13, 2022: Reference Data of Financial Statements for Fiscal 2021

Group Company Corporate April 14, 2022: Former All Blacks players Richard McCaw and Daniel Carter appointed Lipovitan Ambassadors

Holdings Finance February 1, 2022: The 3rd Quarter of Fiscal 2021 Financial Statements

Holdings Finance February 1, 2022: Reference Data of The 3rd Quarter of Fiscal 2021 Financial Statements

2021

Group Company R&D December 20, 2021: Data from Japan's First Phase II/III Clinical Trial of NANOBODY® Ozoralizumab for Rheumatoid Arthritis Presented at the 36th Annual Meeting of the Japanese Society for Clinical Rheumatology and Related Research

Holdings Finance November 9, 2021: The 2nd Quarter of Fiscal 2021 Financial Statements

Holdings Finance November 9, 2021: Reference Data of The 2nd Quarter of Fiscal 2021 Financial Statements

Group Company R&D October 25, 2021: Cetylpyridinium chloride hydrate (CPC) confirmed to have an action inactivating SARS-CoV-2

Group Company Corporate October 8, 2021: Taisho Pharmaceutical appointed as Premium Global Partner of New Zealand Rugby

Holdings Finance August 5, 2021: The 1st Quarter of Fiscal 2021 Financial Statements

Holdings Finance August 5, 2021: Reference Data of The 1st Quarter of Fiscal 2021 Financial Statements

Group Company Corporate June 30, 2021: Taisho and Ancora Bio sign exclusive license agreement for the development, manufacturing, and commercialization of selective vasopressin V1b receptor antagonist, TS-121, worldwide

Holdings Finance June 29, 2021: Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)

Group Company Corporate June 24, 2021: Taisho Pharmaceutical appointed as Official Supplier of Rugby World Cup France 2023

Holdings Corporate May 14, 2021: Notice Concerning the Execution of the Share Exchange Agreement to Make Biofermin Pharmaceutical Co., Ltd. a Wholly-owned Subsidiary of Taisho Pharmaceutical Holdings Co., Ltd.

Holdings Finance May 14, 2021: Financial Statements for Fiscal 2020

Holdings Finance May 14, 2021: Reference Data

Group Company R&D March 22, 2021: Notification of Application for Approval to Manufacture and Market Anti-TNFα multivalent NANOBODY® compound (ozoralizumab) in Japan
Japan's first NANOBODY® Therapeutic

Group Company R&D February 22, 2021: Notification of Application for Approval of Manufacturing and Marketing for Orally Disintegrating Films of SGLT2 Inhibitor Lusefi® Tablets

Holdings Finance February 4, 2021: The 3rd Quarter of Fiscal 2020 Financial Statements

Holdings Finance February 4, 2021: Reference Data

Group Company Corporate January 22, 2021: Taisho and Chugai Terminate the Co-Marketing Agreement of Edirol®,a Treatment for Osteoporosis

2020

Holdings Finance October 29, 2020: The 2nd Quarter of Fiscal 2020 Financial Statements

Holdings Finance October 29, 2020: Reference Data

Holdings Corporate August 31, 2020: Notice Concerning the Termination of the Agreement Between Taisho Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd. on the Distribution of Prescription Drugs of Biofermin Pharmaceutical Co., Ltd.

Holdings Finance August 6, 2020: Notice Concerning Determination of Details of Stock Options (Stock Acquisition Rights)

Holdings Corporate June 26, 2020: Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)

Holdings Finance May 14, 2020: Financial Statements for Fiscal 2019

Holdings Finance May 14, 2020: Reference Data

Group Company R&D April 30, 2020: Taisho and BioAge sign exclusive license agreement for the development, manufacturing, and commercialization of hypoxia inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, TS-143, worldwide

Holdings Finance February 14, 2020: Financial Statements for the 3rd Quarter of Fiscal 2019

Holdings Finance February 14, 2020: Reference Data

Holdings Finance February 14, 2020: Notice of Revision of Forecasts for the Fiscal Year Ending March 31, 2020

Holdings Finance January 30, 2020: Notice of Postponement of Announcement of Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2020

2019

Holdings Finance October 30, 2019: Reference Data

Holdings Finance October 30, 2019: Financial Statements for the 2nd Quarter of Fiscal 2019

Group Company R&D October 1, 2019: Taisho and Moberg Pharma sign exclusive license agreement for the development and commercialization of MOB-015 in Japan

Holdings Corporate July 30, 2019: Notice Concerning Determination of Details of Stock Options (Stock Acquisition Rights)

Holdings Finance July 29, 2019: Reference Data

Holdings Finance July 29, 2019: Financial Statements for the 1st Quarter of Fiscal 2019

Holdings Finance July 29, 2019: Notice of Revision of Half-Year and Full-Year Forecasts for the Fiscal Year Ending March 31, 2020

Holdings Corporate July 2, 2019: Taisho Completed Procedures for the Acquisition of UPSA SAS

Holdings Corporate June 27, 2019: Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)

Holdings Corporate May 20, 2019: Duoc Hau Giang Pharmaceutical JSC became a consolidated subsidiary of Taisho

Holdings Finance May 13, 2019: Reference Data

Holdings Finance May 13, 2019: Financial Statements for Fiscal 2018

Holdings Finance May 13, 2019: Notice Regarding Dividends from Surplus

Holdings Finance May 13, 2019: Notice of Retirement of Treasury Stock

Holdings Corporate April 18, 2019: Notice Regarding the Result of the Tender Offer for Shares of Duoc Hau Giang Pharmaceutical JSC

Holdings Corporate February 28, 2019: Notice Regarding the Tender Offer for Shares of Duoc Hau Giang Pharmaceutical JSC

Holdings Finance January 30, 2019: Reference Data

Holdings Finance January 30, 2019: Financial Statements for the 3rd Quarter of Fiscal 2018

Holdings Corporate January 30, 2019: Notice of Change in a Sub-subsidiary

2018

Holdings Corporate December 19, 2018: Taisho Agreed To Acquire UPSA SAS, A French Pharmaceutical Manufacturer, and its Business Assets, Owned by Bristol-Myers Squibb Company

Holdings Finance October 29, 2018: Reference Data

Holdings Finance October 29, 2018: Financial Statements for the 2nd Quarter of Fiscal 2018

Holdings Finance October 23, 2018: Notice of Revision of Half-Year Forecasts for the Fiscal Year Ending March 31, 2019

Holdings Corporate October 1, 2018: Notice of Termination of Business Alliance with FUJIFILM Holdings Corporation and TOYAMA CHEMICAL CO., LTD. and Change of the System for Sales of Ethical Pharmaceuticals

Holdings Corporate October 1, 2018: Notice of Change of Trade Name of Subsidiary

Holdings Corporate August 31, 2018: Results of Early Retirement Program

Holdings Corporate August 2, 2018: Notice Concerning Determination of Details of Stock Options (Stock Acquisition Rights)

Holdings Finance August 1, 2018: Reference Data

Holdings Finance August 1, 2018: Financial Statements for the 1st Quarter of Fiscal 2018

Holdings Corporate June 28, 2018: Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)

Holdings Finance May 14, 2018: Reference Data

Holdings Finance May 14, 2018: Financial Statements for Fiscal 2017

Holdings Corporate May 14, 2018: "Notice Concerning Acquisition of Shares in Taisho Toyama Pharmaceutical Co., Ltd. (Conversion into a Wholly-Owned Subsidiary) and Sale of Shares in TOYAMA CHEMICAL CO., LTD."

Holdings Corporate May 14, 2018: Implementation of Early Retirement Program

Holdings Finance February 1, 2018: Reference Data

Holdings Finance February 1, 2018: Financial Results for the 3rd Quarter of Fiscal 2017

2017

Group Company General November 1, 2017: Taisho Pharmaceutical Appointed Official Sponsor of Rugby World Cup 2019™ Japan

Holdings Finance October 30, 2017: Reference Data

Holdings Finance October 30, 2017: Financial Results for the 2nd Quarter of Fiscal 2017

Holdings Finance October 25, 2017: Notice of Revision of Half-Year Forecasts for the Fiscal Year Ending March 31, 2018

Group Company Corporate October 13, 2017: Transfer of rights to anti-rheumatic agent KOLBET® Tablets in Japan

Holdings Corporate August 3, 2017: Notice Concerning Determination of Details of Stock Options

Holdings Finance August 2, 2017: Reference Data

Holdings Finance August 2, 2017: Financial Results for the 1st Quarter of Fiscal 2017

Holdings Corporate June 29, 2017: Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)

Holdings Finance May 15, 2017: Reference Data

Holdings Finance May 15, 2017: Financial Statements for Fiscal 2016

Holdings Finance February 2, 2017: Reference Data

Holdings Finance February 2, 2017: Financial Results for the 3rd Quarter of Fiscal 2016

Holdings Corporate January 31, 2017: "Notice Concerning the Termination of the Agreement Between Taisho Pharmaceutical Co., Ltd.
and Takeda Pharmaceutical Co., Ltd. on the Distribution of the OTC Drugs and Quasi-Drugs of Biofermin Pharmaceutical Co., Ltd."

2016

Holdings Corporate December 26, 2016: Notice Concerning Acquisition of Dr. Program Co., Ltd., Consolidated Subsidiary of KYORIN Holdings, Inc.

Holdings General November 29, 2016: Notice of Change in Status of Major Shareholder

Holdings Finance October 31, 2016: Reference Data

Holdings Finance October 31, 2016: Financial Results for the 2nd Quarter of Fiscal 2016

Holdings Finance October 24, 2016: Notice of Revision of Half-Year Forecasts for the Fiscal Year Ending March 31, 2017

Holdings Corporate August 2, 2016: Notice Concerning Determination of Details of Stock Options (Stock Acquisition Rights)

Holdings Finance August 1, 2016: Reference Data

Holdings Finance August 1, 2016: Financial Results for the 1st Quarter of Fiscal 2016

Holdings Corporate July 15, 2016: Signing of Licensing and Commercialization Agreement Regarding OTC Drug Products in Japan for the Allergy Treatment Claritin

Holdings Corporate July 5, 2016: Taisho Completes Acquisition of 24.50% Shares in Duoc Hau Giang Pharmaceutical JSC

Holdings Corporate June 29, 2016: Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)

Holdings Finance May 16, 2016: Reference Data

Holdings Finance May 16, 2016: Financial Statements for Fiscal 2015

Holdings Products April 21, 2016: Launch of the Agent for Osteoporosis “Bonviva® Tablet 100 mg”

Holdings Corporate March 9, 2016: Status of Stock Buyback on Open Market, End of Buyback Program

Holdings Corporate March 1, 2016: Status of Stock Buyback on Open Market

Holdings Finance February 3, 2016: Reference Data

Holdings Finance February 3, 2016: Financial Results for the 3rd Quarter of Fiscal 2015

Holdings Corporate February 3, 2016: Decision on Matters Concerning Stock Buyback

Group Company Corporate January 22, 2016: Agent for Osteoporosis Approved in Japan “Bonviva® Tablet”

Holdings Products January 20, 2016: Launch of the Transdermal Anti-inflammatory Analgesic Patch Formulation LOQOA® Tape